The Swedish risk group.

<p>^a)SvDHV.</p><p>^b)Swedish National Food Agency.</p><p>^c)SJV.</p><p>^d) According to Statistics Sweden, the average Swedish household consists of two persons.</p><p>The Swedish risk group.</p

Event-tree for the risk group with respect to LA-MRSA interventions.

<p>Event-tree for the risk group with respect to LA-MRSA interventions.</p

Expected benefits (95 percent credibility intervals) when preventing LA-MRSA from being introduced into the Swedish pig population assuming human prevalence as in, respectively, Denmark and the Netherlands (€, 2011 prices).

<p>^a Prevalence independent</p><p>Expected benefits (95 percent credibility intervals) when preventing LA-MRSA from being introduced into the Swedish pig population assuming human prevalence as in, respectively, Denmark and the Netherlands (€, 2011 prices).</p

MRSA-related costs in Swedish health care (€, 2011 prices).

<p>^a)County Council of Västra Götaland [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref038" target="_blank">38</a>] and County Council of Örebro [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref039" target="_blank">39</a>].</p><p>^b)Västra Götalandsregionen [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref040" target="_blank">40</a>].</p><p>^c)Personal communication, County Council of Skåne.</p><p>^d)Antibiotics recommended for policlinic treatment of MRSA-infections, trimethoprim-sulphonamide or fusidic acid [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref042" target="_blank">42</a>], are no more costly than flucloxacillin, the antibiotic recommended for treatment of sensitive infections [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref028" target="_blank">28</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref041" target="_blank">41</a>]. As to antibiotics used for severe infections in inpatient care, vancomycin costs about the same as cloxacillin—recommended for treatment of severe sensitive infections [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref041" target="_blank">41</a>]—linezolid, however, used in about 20 percent of MRSA cases (personal communication, Public Health Agency of Sweden), is € 374 more expensive than cloxacillin. Costs are based on prices from Swedish Pharmacies [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref041" target="_blank">41</a>].</p><p>MRSA-related costs in Swedish health care (€, 2011 prices).</p

Break-even rates of herd prevalence of LA-MRSA in the exporting country.

<p>Break-even rates of herd prevalence of LA-MRSA in the exporting country.</p

Profit maximisation with and without the preventive measures.

<p>Profit maximisation with and without the preventive measures.</p

Expected annual number of visits and probabilities in Fig 1.

<p>^a)Estimated using data from Swedish Board of Health and Welfare and SKL.</p><p>^b)Estimated using data from Andre et al [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref031" target="_blank">31</a>] and Swedish Board of Health and Welfare.</p><p>^c) Voss et al. [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref032" target="_blank">32</a>], Wulf et al. [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref037" target="_blank">37</a>], van den Broek et al. [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref033" target="_blank">33</a>], van Cleef et al [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref034" target="_blank">34</a>].</p><p>^d)van den Broek et al. [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref033" target="_blank">33</a>].</p><p>^e)van Cleef et al. [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref035" target="_blank">35</a>], and Gilbert et al [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref036" target="_blank">36</a>].</p><p>^f)Wulf et al [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref037" target="_blank">37</a>].</p><p>^g)Computed from <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.t001" target="_blank">Table 1</a> above.</p><p>^h)Personal communication, FOI.</p><p>Expected annual number of visits and probabilities in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.g001" target="_blank">Fig 1</a>.</p

Probability of at least one boar being MRSA-positive, annual number of imported boars, batches, insemination doses produced per boar, and prices of insemination doses (€, 2011 prices).

<p>^a)Based on the herd prevalence of MRSA in Norway in 2012 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0122875#pone.0122875.ref047" target="_blank">47</a>].</p><p>^b)Personal communication, breeding companies.</p><p>^c)Breeding companies’ home pages [45, 46 both accessed 2014-04-23.</p><p>Probability of at least one boar being MRSA-positive, annual number of imported boars, batches, insemination doses produced per boar, and prices of insemination doses (€, 2011 prices).</p

Cost for MRSA-test, destruction of MRSA-positive boars (€, 2011 prices) and price elasticity.

<p>^a)Personal communication SJV and SvDHV.</p><p>^b) Personal communication SVA.</p><p>^c)Personal communication Svensk Lantbrukstjänst.</p><p>^d)Breeding companies’ homepages (<a href="http://avelspoolen.se" target="_blank">http://avelspoolen.se</a> and <a href="http://www.qgenetics.se" target="_blank">http://www.qgenetics.se</a>) both accessed 2014-04-23.</p><p>Cost for MRSA-test, destruction of MRSA-positive boars (€, 2011 prices) and price elasticity.</p

Expected annual number of visits by patients in the risk group in each part of the event tree given Danish and Dutch prevalence (rounded to integers).

<p>Expected annual number of visits by patients in the risk group in each part of the event tree given Danish and Dutch prevalence (rounded to integers).</p